A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers*
References (33)
- et al.
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Neuropharmacology
(2007) Tobacco or Health: A Global Status Report
(1997)- et al.
The Tobacco Atlas
(2006) - et al.
Smoking behaviour in Taiwan, 2001
Tob Control
(2005) - et al.
Smoking and cause of death in Korea: 11 Years follow-up prospective study
Korean J. Epidemiol
(2005) - et al.
Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios
Tob Control
(2005) Bupropion
Drugs Today (Barc)
(2006)
Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy
Psychopharmacology (Berl)
(2006)
Tolerability and safety of sustained-release bupropion in the management of smoking cessation
Drugs
(2002)
Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: A preliminary investigation
Psychopharmacology (Berl)
(2005)
Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3 beta4 subtypes in rat tissues by autoradiography
J Neurochem
(2002)
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
Nature
(2005)
Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation
J Med Chem
(2005)
Cited by (0)
- *
The data in this manuscript were presented in part at the 15th WONCA 2006 Asia Pacific Regional Conference, Bangkok, Thailand, November 5–9, 2006.
Copyright © 2007 Published by Elsevier Inc.